TGFb inhibitors Pipeline Insight Report 2021: In 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “TGFb inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The companies and academics are working to assess challenges and seek opportunities that could influence TGFb inhibitors R&D. The therapies under development are focused on novel approaches for TGFb inhibitors.

In July 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio.

TGFb inhibitors Emerging Drugs Chapters

This segment of the TGFb inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TGFb inhibitors Emerging Drugs

• Luspatercept – Acceleron Pharma

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.

TGFb inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TGFb inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TGFb inhibitors

There are approx. 10+ key companies which are developing the TGFb inhibitors. The companies which have their TGFb inhibitors drug candidates in the most advanced stage, i.e. phase III include, Luspatercept.

The report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

TGFb inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TGFb inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGFb inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGFb inhibitors drugs.

TGFb inhibitors Report Insights

• TGFb inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TGFb inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing TGFb inhibitors drugs?
• How many TGFb inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for TGFb inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TGFb inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TGFb inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Acceleron Pharma
• Isarna Therapeutics
• Forbius

Key Players

• Luspatercept
• ISTH0036
• ISTH1106
• ISTH0047
• ISTH1047
• AVID 200

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2fdjhj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900